Back to Results
First PageMeta Content
Oncology / Melanoma / Organochlorides / Vemurafenib / Dacarbazine / Ipilimumab / BRAF / Protein kinase inhibitor / End point of clinical trials / Chemistry / Medicine / Organofluorides


dabrafenib, 50mg and 75mg hard capsules (Tafinlar®) GlaxoSmithKline SMC No. (No[removed]February 2015
Add to Reading List

Open Document

File Size: 460,72 KB

Share Result on Facebook

Company

Patient Access Scheme Assessment Group / GlaxoSmithKline / Oncology Group / European Organization of Research / /

Country

United Kingdom / Scotland / /

Currency

GBP / /

Event

FDA Phase / /

IndustryTerm

anticancer medicinal products / treatment of melanoma / treatment of unresectable or metastatic melanoma / above product / chemical instability / Treatment of Cancer / therapy of metastatic disease / pharmaceutical company funding / treatment algorithm / food / /

MedicalCondition

Solid Tumours / squamous cell carcinoma / measurable disease / BRAF V600 mutated-metastatic melanoma / cancer / disease / arthralgia / headache / BRAFV600 mutation-positive metastatic melanoma / leukopenia / photographic disease / BRAF-mutant melanoma / symptomatic / bulky metastases / IV melanoma / neutropenia / nausea / tumour / thrombocytopenia / advanced melanoma / metastatic disease / vomiting / pain / melanoma / positive metastatic melanoma / myocardial infarction / fatigue / keratoacanthoma / infection / Cutaneous Melanoma / metastases / rash / syndrome / metastatic melanoma / /

MedicalTreatment

immunotherapies / chemotherapy / intravenous infusion / immunotherapy / /

Organization

European Organization of Research and Treatment of Cancer / American Joint Committee on Cancer / European Association of Dermato-Oncology / European Society for Medical Oncology / NHS / British Association of Dermatology / /

Position

investigator / Vice Chairman / qualified physician / Co-operative / /

Product

dacarbazine / BREAK-2 / /

Technology

alpha / treatment algorithm / chemotherapy / /

SocialTag